Indicators of therapeutic effect in FIT-06, a Phase II trial of a DNA vaccine, GTU®-Multi-HIVB, in untreated HIV-1 infected subjects

Vaccine

Volumn 30, Issue 27, 2012, Pages 4046-4054

  Vardas, Eftyhia ^a,b   Stanescu, Ioana ^c   Leinonen, Mika ^d   Ellefsen, Kim ^e   Pantaleo, Giuseppe ^e   Valtavaara, Minna ^c   Ustav, Mart ^f   Reijonen, Kalevi ^c  

^a LANCET LABORATORIES   (South Africa)

^b UNIVERSITY OF STELLENBOSCH   (South Africa)

^c FIT Biotech Ltd   (Finland)

^d 4Pharma Ltd   (Finland)

^e LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

^f FIT Biotech Ltd   (Estonia)

Author keywords

Chronic HIV 1; South africa; Therapeutic HIV 1 vaccines; Untreated

Indexed keywords

DNA VACCINE; ENVELOPE PROTEIN; GTU; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MULTI HUMAN IMMUNODEFICIENCY VIRUS 1 B VACCINE; NEF PROTEIN; PLACEBO; PLASMID DNA; POL PROTEIN; REV PROTEIN; TRANSACTIVATOR PROTEIN; UNCLASSIFIED DRUG; VIRUS RNA;

ADULT; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DRUG EFFECT; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; FEMALE; HAPLOTYPE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE BLEEDING; LYMPHADENOPATHY; MAJOR CLINICAL STUDY; MALE; PHASE 2 CLINICAL TRIAL; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE BLIND PROCEDURE; SKIN INDURATION; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; VIRUS ISOLATION; VOMITING;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ADULT; AIDS VACCINES; CD4 LYMPHOCYTE COUNT; DRUG TOXICITY; FEMALE; GENOTYPE; HIV-1; HUMANS; IMMUNOTHERAPY; INJECTIONS, INTRADERMAL; INJECTIONS, INTRAMUSCULAR; MALE; PLACEBOS; PLASMIDS; RNA, VIRAL; SOUTH AFRICA; TREATMENT OUTCOME; VACCINES, DNA; VACCINES, SYNTHETIC; VIRAL LOAD; YOUNG ADULT;

EID: 84861478669     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.04.007     Document Type: Article

References (33)

1. Virgin H.W., Walker B.D. Immunology and the elusive AIDS vaccine. Nature 2010, 464(March):224-231.
2. Gandhi R.T., Altfeld M. The quest for an HIV-1 therapeutic vaccine. Journal of Infectious Diseases 2005, 192(August (4)):556-559.
3. Richman D.D., Margolis D.M., Delaney M., Greene W.C., Hazuda D., Pomerantz R.J. The challenge of finding a cure for HIV infection. Science 2009, 323(March (5919)):1304-1307.
4. Dorrell L. Therapeutic immunization for the control of HIV-1: where are we now?. International Journal of STD and AIDS 2006, 17(July (7)):436-441.
5. Kinloch-de L.S., Autran B. HIV-1 therapeutic vaccines. Journal of Infection 2002, 44(April (3)):152-159.
6. Peters B.S. The basis for HIV immunotherapeutic vaccines. Vaccine 2001, 20(December (5-6)):688-705.
7. Imami N., Hardy G., Burton C., Pires A., Pido-Lopez J., Moss R., Gazzard B., Gotch F. Immune responses and reconstitution in HIV-1 infected individuals: impact of anti-retroviral therapy, cytokines and therapeutic vaccination. Immunology Letters 2001, 79(November (1-2)):63-76.
8. Leydon N.G., Venter F., Webster P.D., Moleko W., Osler M., Barker P.M. Achieving the HIV and AIDS National Strategic Plan: a practical calculator for local target setting in district health facilities. South African Medical Journal 2010, 100(July (7)):420-424.
9. Virgin H.W., Walker B.D. Immunology and the elusive AIDS vaccine. Nature 2010, 464(11):224-231.
10. Girard M.P., Osmanov S.K., Kieny M.P. A review of vaccine research and development: the human immunodeficiency virus (HIV). Vaccine 2006, 24(May (19)):4062-4081.
11. Wahren B., Liu M. Therapeutic vaccination against HIV. Expert Review of Vaccines 2004, 3(August (4 Suppl.)):S179-S188.
12. Gotch F., Hardy G., Imami N. Therapeutic vaccines in HIV.1 infection. Immunological Reviews 1999, 170(August):173-182.
13. Pai V., Tulsky J.P., Lawrence J., Colford J.M., Reingold A.L. Structured treatment interuptions (STI) in chronic suppressed HIV infection in adults (review). Cochrane Database of Systematic Reviews 2005, (4):1-49.
14. Gotch F. Therapeutic vaccines and immunotherapy revisited. Journal of HIV Therapy 2005, 10(September (3)):48-50.
15. Niu L., Termini J.M., Kanagavelu S.K., Gupta S., Rolland M.M., Kulkarni V., et al. Preclinical evaluation of HIV-1 therapeutic ex vivo dendritic cell vaccines expressing consensus gag antigens and conserved epitopes. Vaccine 2011, 29(January):2110-2119.
16. García F., Climent N., Assoumou L., Gil C., González N., Alcamí J., et al. A therapeutic dendritic cell-based vaccine for HIV-1 infection. Journal of Infectious Diseases 2011, 203(February):473-478.
17. Autran B., Debre P., Walker B., Katlama C. Therapeutic vaccines against HIV need international partnerships. Nature Reviews Immunology 2003, 3(June (6)):503-508.
18. Autran B., Murphy R.L., Costagliola D., Tubiana R., Clotet B., Gatell J., et al. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS 2008, 22(July (11)):1313-1322.
19. Endsley A.N., Salama N.N., Ho R.J. Combining drug and immune therapy: a potential solution to drug resistance and challenges of HIV vaccines?. Current HIV Research 2008, 6(September (5)):401-410.
20. Autran B., Carcelain G., Combadiere B., Debre P. Therapeutic vaccines for chronic infections. Science 2004, 305(July (5681)):205-208.
21. Averitt D. Rebuilding the immune system. World 1999, (April (96)):1-2.
22. Boulle A., Bock P., Osler M., Cohen K., Channing L., Hilderbrand K., et al. Antiretroviral therapy and early mortality in South Africa. Bulletin of the World Health Organization 2008, 86(9):678-687.
23. Krohn K., Stanescu I., Blasevic V., Vesikari T., Ranki A., Ustav M. A DNA HIV-1 vaccine based on a fusion gene expressing non-structural and structural genes of consensus sequence of the A-C subtypes and the ancestor sequence of the F-H subtypes. Preclinical and clinical studies. Microbes and Infection 2005, 7(14):1405-1413.
24. Blazevic V., Männik A., Malm M., Sikut R., Valtavaara M., Toots U., et al. Induction of human immunodeficiency virus type-1-specific immunity with a novel gene transport unit (GTU)-multiHIV DNA vaccine. AIDS Research and Human Retroviruses 2006, 22(July (7)):667-677.
25. Ustav M., Ustav E., Szymanski P., Stenlund A. Identification of the origin of replication of bovine papillomavirus and characterisation of the viral origin recognition factor E1. EMBO Journal 1991, 10:4321-4329.
26. Ilves I., Kivi S., Ustav M. Long-term episomal maintenance of bovine papillomavirus type 1 plasmids is determined by attachment to host chromosomes, which is mediated by the viral E2 protein and its binding sites. Journal of Virology 1999, 73:4404-4412.
27. Department of Health (South Africa) National Strategic Plan for HIV and AIDS/Comprehensive HIV and AIDS Treatment Plan Statistics Memorandum 2007, Department of Health, Pretoria.
28. Casado C., Colombo S., Rauch A., Martínez R., Günthard H.F., Garcia S., et al. Host and viral genetic correlates of clinical definitions of HIV-1 disease progression. PLoS One 2010, 5(June (6)):1-6.
29. Schultz K.F., Altman D.C., Moher D. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. Annals of Internal Medicine 2010, 152(11):1-11.
30. Xie J., Lu W., Samri A., Costagliola D., Schnuriger A., da Silva B.C., et al. Distinct differentiation profiles of HIV-Gag and Nef-specific central memory CD8 cells associated with HLA-B57/5801. AIDS 2010, 24:2323-2329.
31. Ross A.L., Brave A., Scarlatti G., Manrique A., Buonaguro L. Progress towards development of an HIV vaccine: report of the AIDS vaccine 2009 Conference. Lancet Infectious Diseases 2010, 10(May (5)):305-316.
32. Department of Health (South Africa) National Antenatal Sentinel HIV & Syphilis Prevalence Survey in South Africa 2008 2009, Department of Health, Pretoria.
33. Rehle T.M., Hallett T.B., Shisana O., Pillay-van Wyk V., Zuma K., Carrara H., et al. A decline in new HIV infections in South Africa: estimating HIV incidence from three national HIV surveys in 2002, 2005 and 2008. PLoS One 2010, 5(June (6)):1-8.